Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
Bergström, Anders; Maurel, Frédérique; Le Pen, Claude; Lamure, Emilie; Kent, Michael; Bardoulat, Isabelle; Berdeaux, Gilles (2009), Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden, Clinical Ophthalmology, 3, p. 471-481
TypeArticle accepté pour publication ou publié
External document linkhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732058
Journal nameClinical Ophthalmology
MetadataShow full item record
Le Pen, Claude
Abstract (EN)Background: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden). Methods: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardized procedures. Residual drops were then counted. Unit bottle costs were estimated from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising drug, instillation day, country, the interaction, and a sample factor nested within the country factor. Effectiveness was represented by treatment failure rates estimated from a meta-analysis and a general practitioner survey. Results: Every drug bottle contained sufficient drops to treat 1 patient for 28/31 days. Drop-size heterogeneity between countries was observed for bimatoprost and bimatoprost/timolol. Mean travoprost and travoprost/timolol drop-sizes were the smallest, and drop-counts per bottle were the lowest for latanoprost, or latanoprost/timolol. In all 4 countries annual costs were least for travoprost and travoprost/timolol. Conclusions: On taking into account drug costs and effectiveness, travoprost and travoprost/timolol were cheaper and more effective than latanoprost and latanoprost/timolol and were cheaper than bimatoprost and bimatoprost/timolol.
Subjects / KeywordsEconomics; daily cost; prostaglandin analogue
Showing items related by title and author.
Le Pen, Claude; Schadtler Law, L.; Camara, Catherine; Bardoulat, Isabelle; Maurel, F. (2009-10) Communication / Conférence
Le Pen, Claude; Bardoulat, Isabelle; Preiss, P.; Schadtler Law, L.; Fautrel, B.; Maurel, F. (2009) Article accepté pour publication ou publié
Cost-effectiveness of using etanercept as first Line in severe and highly active rheumatoid Arthritis (ra) Le Pen, Claude; Miadi-Fargier, Houda; Daures, JP.; Maurel, F.; Fautrel, B.; Maravic, M. (2008) Article accepté pour publication ou publié
Effectiveness of a Lumbar Belt in Subacute Low Back Pain: An Open, Multicentric, and Randomized Clinical Study Lerouvreur, Claire; Maurel, Frederique; Le Pen, Claude; Hamonet, Claude; Queneau, Patrice; Calmels, Paul; Thoumie, Philippe (2009-02) Article accepté pour publication ou publié
Diagnosis Related Group Costs in a Regulated Environment: A Note About Their Economic Interpretation Berdeaux, Gilles; Le Pen, Claude (2000) Article accepté pour publication ou publié